News | 04 November 2022
GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Once the unit is made fully functional, it will help the company in increasing its API and intermediate production capacity
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Subscribe To Our Newsletter & Stay Updated
